<DOC>
	<DOCNO>NCT02995694</DOCNO>
	<brief_summary>The purpose study determine therapeutic equivalence Alvogen 's estradiol vaginal cream Estrace® cream superiority product placebo . The protocol describe randomize , double-blind , multi-dose , placebo-controlled , parallel study 7 day treatment .</brief_summary>
	<brief_title>A Multi-Site Study Comparing Estradiol Vaginal Cream ( 0.01 % ) Estrace® Cream ( 0.01 % ) Postmenopausal Females With Atrophic Vaginitis</brief_title>
	<detailed_description />
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Atrophic Vaginitis</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>1 . Signed Informed Consent meet criteria current FDA regulation 2 . Females age : 3075 year old inclusive postmenopausal . 3 . Postmenopausal define least 12 month spontaneous amenorrhea least 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/ml least 6 week postsurgical bilateral oophorectomy without hysterectomy . Hysterectomy without oophorectomy age investigator believe would naturally reach 12 month spontaneous amenorrhea . 4 . Baseline evaluation requirement : ≤5 % superficial cell vaginal smear cytology Vaginal pH &gt; 5.0 At least one patient selfassessed moderate severe symptom vulvar and/or vaginal atrophy ( VVA ) follow list identify subject : Vaginal dryness Vaginal and/or vulvar irritation/itching Dysuria Vaginal pain associate sexual activity* Vaginal bleeding associate sexual activity ( absence vs. presence ) * *provided patient currently sexually active plan remain throughout study . 5 . Normal breast exam screen mammogram complete within 9 month prior screen patient &gt; 40 year old . 6 . For woman intact uterus , endometrial thickness &lt; 4 mm determine vaginal ultrasonography . 7 . Documented PAP smear conduct within previous 12 month finding Investigator believe would contraindicate use topical vaginal estradiol 1 . Females young 30 year age old 75 year age 2 . Patients serum FSH level ≤ 40mIU/ml screening . 3 . Greater 5 % superficial cell vaginal cytology . 4 . Vaginal pH ≤ 5 5 . Significant history current evidence chronic infectious disease , system disorder , organ disorder ( include significant liver/kidney impairment ) medical condition Investigator 's opinion would place study patient undue risk participation could jeopardize integrity study evaluation . 6 . Patients intact uterus vaginal ultrasonography result confirm inactive endometrial lining . Patients endometrial thickness equal great 4mm exclude . 7 . Patients know , suspected current history carcinoma breast . All patient age 40 must mammogram perform within 9 month study start patient physical breast exam perform screen . 8 . Patients baseline systolic blood pressure &gt; 150mm Hg and/or diastolic pressure &gt; 90 mm Hg 9 . Any patient undiagnosed vaginal bleeding significant risk factor endometrial cancer . 10 . Any history estrogendependent neoplasia ( e.g. , endometrial cancer ) .</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>